Immune Checkpoint Inhibitors in Cancer Therapy - PMC
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139602/
WebApr 24, 2022 · The US FDA has successfully approved three different categories of immune checkpoint inhibitors (ICIs) such as PD-1 inhibitors (Nivolumab, Pembrolizumab, and Cemiplimab), PDL-1 inhibitors (Atezolimumab, Durvalumab and Avelumab), and CTLA-4 inhibitor (Ipilimumab).
DA: 65 PA: 90 MOZ Rank: 22 Up or Down: Up